Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women.

Martinez-Rebollar M, Lonca M, Perez I, Soy D, Brunet M, Martin R, Coll O, Hernandez S, Laguno M, Milinkovic A, Larrousse M, Calvo M, Blanco JL, Martínez E, Gatell JM, Mallolas J.

Ther Drug Monit. 2011 Dec;33(6):772-7. doi: 10.1097/FTD.0b013e318236376d.

PMID:
22105596
2.

Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy.

von Hentig N, Nisius G, Lennemann T, Khaykin P, Stephan C, Babacan E, Staszewski S, Kurowski M, Harder S, Haberl A.

Antivir Ther. 2008;13(8):1039-46.

PMID:
19195329
3.

Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects.

Cardiello PG, Monhaphol T, Mahanontharit A, van Heeswijk RP, Burger D, Hill A, Ruxrungtham K, Lange JM, Cooper DA, Phanuphak P.

J Acquir Immune Defic Syndr. 2003 Apr 1;32(4):375-9.

PMID:
12640194
4.

Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy.

Lopez-Cortes LF, Ruiz-Valderas R, Rivero A, Camacho A, Marquez-Solero M, Santos J, García-Lazaro M, Viciana P, Rodriguez-Baños J, Ocampo A.

Ther Drug Monit. 2007 Apr;29(2):171-6.

PMID:
17417070
5.

The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women.

van der Lugt J, Colbers A, Molto J, Hawkins D, van der Ende M, Vogel M, Wyen C, Schutz M, Koopmans P, Ruxrungtham K, Richter C, Burger D; SARA study team.

Antivir Ther. 2009;14(3):443-50.

PMID:
19474478
6.

Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.

van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM.

AIDS. 2000 Jun 16;14(9):F103-10.

PMID:
10894270
7.

Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.

Veldkamp AI, van Heeswijk RP, Mulder JW, Meenhorst PL, Schreij G, van der Geest S, Lange JM, Beijnen JH, Hoetelmans RM.

J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):344-9.

PMID:
11468422
8.

Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.

Ribera E, Azuaje C, Lopez RM, Domingo P, Curran A, Feijoo M, Pou L, Sánchez P, Sambeat MA, Colomer J, Lopez-Colomes JL, Crespo M, Falcó V, Ocaña I, Pahissa A.

J Antimicrob Chemother. 2007 Apr;59(4):690-7. Epub 2007 Feb 16.

PMID:
17307771
9.

Reduced lopinavir exposure during pregnancy.

Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, Cotter A, Read JS.

AIDS. 2006 Oct 3;20(15):1931-9.

PMID:
16988514
11.

Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.

Ripamonti D, Cattaneo D, Maggiolo F, Airoldi M, Frigerio L, Bertuletti P, Ruggeri M, Suter F.

AIDS. 2007 Nov 30;21(18):2409-15.

PMID:
18025877
12.

Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats.

Shibata N, Kageyama M, Kishida T, Kimura K, Yoshikawa Y, Kuwahara T, Toh J, Shirasaka T, Takada K.

Biopharm Drug Dispos. 2003 Nov;24(8):335-44.

PMID:
14595702
13.

Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women.

Acosta EP, Bardeguez A, Zorrilla CD, Van Dyke R, Hughes MD, Huang S, Pompeo L, Stek AM, Pitt J, Watts DH, Smith E, Jiménez E, Mofenson L; Pediatric AIDS Clinical Trials Group 386 Protocol Team,.

Antimicrob Agents Chemother. 2004 Feb;48(2):430-6.

14.

Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.

Ribera E, Lopez RM, Diaz M, Pou L, Ruiz L, Falcó V, Crespo M, Azuaje C, Ruiz I, Ocaña I, Clotet B, Pahissa A.

Antimicrob Agents Chemother. 2004 Nov;48(11):4256-62.

15.

Reduced indinavir exposure during pregnancy.

Cressey TR, Best BM, Achalapong J, Stek A, Wang J, Chotivanich N, Yuthavisuthi P, Suriyachai P, Prommas S, Shapiro DE, Watts DH, Smith E, Capparelli E, Kreitchmann R, Mirochnick M; IMPAACT P1026s team.

Br J Clin Pharmacol. 2013 Sep;76(3):475-83. doi: 10.1111/bcp.12078.

16.

Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.

Kurowski M, Müller M, Donath F, Mrozikiewicz M, Möcklinghoff C.

Eur J Med Res. 1999 Mar 26;4(3):101-4.

PMID:
10085276
18.

Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.

Cardiello PG, van Heeswijk RP, Hassink EA, Srasuebkul P, Mahanontharit A, Samor TM, Worarien W, Beijnen JH, Hoetelmans RM, Ruxrungtham K, Cooper DA, Lange JM, Phanuphak P.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):464-70.

PMID:
11981362
19.

Effectiveness and safety of saquinavir/ritonavir in HIV-infected pregnant women: INEMA cohort.

Brunet C, Reliquet V, Jovelin T, Venisse N, Winer N, Bui E, Le Moal G, Perfezou P, De Saint Martin L, Raffi F.

Med Mal Infect. 2012 Sep;42(9):421-8. doi: 10.1016/j.medmal.2012.07.010. Epub 2012 Aug 28.

PMID:
22938775
20.

Supplemental Content

Support Center